Breakthrough in genetically engineered treatment for sickle cell disease

Breakthrough in genetically engineered treatment for sickle cell disease

**Current Status of Exa-cel (Exagamglogene autotemcel, Casgevy®): A Revolutionary Gene Therapy for Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia**

Exa-cel, a groundbreaking CRISPR-based gene therapy developed by the collaboration between CRISPR Therapeutics and Vertex Pharmaceuticals, has received a significant milestone in its journey towards revolutionising the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).

On February 9, 2024, the European Medicines Agency (EMA) granted conditional marketing authorization for Exa-cel, making it the first CRISPR-based therapy to be approved for these conditions in the European Union (EU). The approval is for patients aged 12 years or older who are eligible for hematopoietic stem cell transplantation but lack a human leukocyte antigen (HLA)-matched related donor.

In the United States, while there is no specific mention of Exa-cel receiving regulatory approval as of now, Vertex Pharmaceuticals is actively pursuing approval through the rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration. The company expects to complete the BLA submission by the end of the first quarter.

The development and approval of Exa-cel mark a significant leap forward in the treatment of SCD and TDT. Exa-cel, formerly known as CTX001, is an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy. It works by collecting patients' hematopoietic stem and progenitor cells from peripheral blood, editing them using CRISPR/Cas9 technology, and infusing the edited cells back into the patient as part of an autologous hematopoietic stem cell transplant (HSCT) following myeloablative busulfan conditioning.

After engraftment, patients are continuously monitored to track the impact of Exa-cel on multiple measures of disease and for safety. The engraftment process, where edited cells begin to produce mature blood cells, is a crucial step in the treatment.

Nia Tatsis, executive vice president and chief regulatory and quality officer at Vertex, stated that this approval marks a significant milestone in their efforts to bring a new one-time therapy to people living with SCD or TDT.

The partnership between Vertex and CRISPR Therapeutics was established in 2015 to focus on using CRISPR/Cas9 to discover and develop potential new treatments for human disease. The collaboration has been fruitful, with Exa-cel being the first potential treatment to emerge from this joint research program. Vertex now leads global development, manufacturing, and commercialization of the therapy.

In addition to the EU approval, Exa-cel has also been granted Priority Medicines (PRIME) designation for both SCD and TDT by the EMA. It has also received Orphan Drug Designation from the European Commission for both conditions. The submission is supported by two global phase 3 studies investigating Exa-cel as a potential one-time therapy for people with SCD or TDT.

As commercial uptake of Exa-cel in the EU has been slow due to the complexity of the treatment process, CRISPR Therapeutics, along with Vertex, continues to advance other CRISPR candidates and explore new therapeutic areas, including in vivo gene therapies. Despite the challenges, the approval of Exa-cel in the EU is a significant step towards reducing or eliminating painful and debilitating vaso-occlusive crises for patients with SCD and alleviating transfusion requirements for patients with TDT.

1. The pharmaceutical industry, particularly biopharma companies like Vertex Pharmaceuticals, are actively pursuing technology-driven solutions in the health-and-wellness sector, with Exa-cel, a CRISPR-based gene therapy, poised to revolutionize the treatment of medical-conditions such as sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).
2. In the realm of science, technology, and medical-conditions, Exa-cel has been granted conditional marketing authorization by the European Medicines Agency (EMA) for patients with SCD or TDT who lack a human leukocyte antigen (HLA)-matched related donor, marking a significant advancement in the treatment of these conditions.
3. The approval of Exa-cel in the European Union (EU) signifies a major breakthrough in the biotech and pharmaceuticals sector, as it is the first CRISPR-based therapy to be approved for these conditions, paving the way for new approaches to tackle medical-conditions and improve health-and-wellness for those affected.

Read also: